
|Videos|May 3, 2022
Pharmaceutical CEO Leadership: Real-World Evidence
Among the topics discussed at Pharm Exec’s recent RWE roundtable are how the pandemic has served to validate the use of RWE/RWD; the most important features of a real-world data set; and key considerations when selecting an RWD partner.
Advertisement
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Roche and C4 Therapeutics Expands Partnership with $1 Billion Collaboration Agreement
2
Shionogi Inc. Awarded $482 Million Contract with U.S. Government to Enhance National Preparedness for Drug-Resistant Bacterial Threats
3
Pharmaceutical Executive Daily: Shah Capital's Plan to Vote Against Novavax Board Nominees
4
Lipid Lowering with PCSK9 Inhibition: Long-Term Efficacy, Long-Standing Barriers
5




